Price$0.41+0.00 (+1.01%)
02:00 PM07:45 PM
News · 26 weeks31-89%
2025-12-072026-05-31
Mix2190d
- Insider8(38%)
- Other7(33%)
- Analyst3(14%)
- SEC Filings3(14%)
Latest news
25 items- PRSystemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patientsSYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced results from a systematic evaluation of 5 clinical trials of eftilagimod alfa ("efti") an antigen-presenting cell (APC) activator in combination with standard-of-care (SOC) therapies in late-stage cancer patients. In these trials, treatment with 30 mg subcutaneous (SC) efti plus SOC resulted in a significant increase in circulating absolute lymphocyte count (ALC), a blood-based measure of immune activity, compared to SOC alone where this effect was not seen. More important
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep Receives Nasdaq Notice of Bid Price DeficiencySYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company's American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement. The notification has no immediate effect on the listing or trading of the Company's American Depositary Sh
- PRImmutep Quarterly Activities Report Q3 FY26Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under reviewPhase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions. SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biot
- PRImmutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual MeetingSYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract has been selected for poster presentation at the upcoming 2026 American Society of Clinical Oncology's (ASCO) Annual Meeting, taking place in-person and online from 29 May-2 June 2026 in Chicago, Illinois (United States). The accepted abstract, titled "Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients," will be presented within the Developmental Therapeutics—Immunotherap
- INSIDERSEC Form 3 filed by new insider Boyce Elisabeth Amanda3 - IMMUTEP Ltd (0001506184) (Issuer)
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue SarcomaSYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa ("efti") for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA's Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exe
- INSIDERSEC Form 3 filed by new insider Voigt Marc3 - IMMUTEP Ltd (0001506184) (Issuer)
- INSIDERSEC Form 3 filed by new insider Miller Deanne Diem3 - IMMUTEP Ltd (0001506184) (Issuer)
- INSIDERSEC Form 3 filed by new insider Meyers Pete A.3 - IMMUTEP Ltd (0001506184) (Issuer)
- INSIDERSEC Form 3 filed by new insider Winckels Stephan Karel Gerard3 - IMMUTEP Ltd (0001506184) (Issuer)
- INSIDERSEC Form 3 filed by new insider Triebel Frederic Joseph Daniel3 - IMMUTEP Ltd (0001506184) (Issuer)
- INSIDERSEC Form 3 filed by new insider Howard Russell J3 - IMMUTEP Ltd (0001506184) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mueller Christian3 - IMMUTEP Ltd (0001506184) (Issuer)
- PRImmutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune DiseasesImmutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026 SYDNEY, AUSTRALIA, March 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants evaluating IMP761, a first-in-class LAG-3 agonist antibody which enhances the physiological inhibitory function of LAG-3 on T-cell receptor s
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- ANALYSTImmutep downgraded by Maxim GroupMaxim Group downgraded Immutep from Buy to Hold
- ANALYSTImmutep downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Immutep from Outperform to Neutral and set a new price target of $1.00
- ANALYSTImmutep downgraded by CitizensCitizens downgraded Immutep from Mkt Outperform to Mkt Perform
- PRTACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility AnalysisIndependent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ("efti") in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol. Based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility. In
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- ANALYSTCitizens initiated coverage on Immutep with a new price targetCitizens initiated coverage of Immutep with a rating of Mkt Outperform and set a new price target of $6.00
- PRImmutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLCThe registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient enrolment target in the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc.,
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
IMMP FAQ
6 questionsWhat does Immutep Limited do?
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck...Where does IMMP stock trade?
Immutep Limited (IMMP) is listed on NASDAQ.What sector and industry is IMMP in?
Immutep Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IMMP?
Immutep Limited has had 8 recent analyst actions on file. The most recent action was from Maxim Group: Hold on 2026-03-13.What companies are similar to IMMP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMMP side-by-side with any of them on Quantisnow.How can I track IMMP on Quantisnow?
Quantisnow aggregates Immutep Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMMP to receive live email and push alerts on every new disclosure.